Abnormal Liver Tests and MASLD
Current BC and Canadian guidelines, algorithms, tools, prescribing references and patient resources for nurse practitioners.
Reviewed by Joe Grafe Due
Review overdue
This page was due for review on November 8, 2027. Check the linked sources for newer versions before relying on it.
Key Sources¶
- BC Guidelines - Abnormal Liver Chemistry: Evaluation and Interpretation (2011) · PDF — BC GPAC; working up abnormal liver enzymes and liver function tests in adults
Canadian Association for the Study of the Liver - MASLD Clinical Practice Guidance (2026)
assessment and management of metabolic dysfunction-associated steatotic liver disease, including fibrosis risk testing; Can Liver J 9(3):345-388
- Approach to steatotic liver disease in the office: Diagnosis, management, and proposed nomenclature (Canadian Family Physician) (2025) · PDF — Can Fam Physician 71(4):249-254; includes a management algorithm and the new names
Further Resources¶
- BC Guidelines - Abnormal Liver Chemistry: Evaluation and Interpretation (2011) · PDF — BC GPAC; working up abnormal liver enzymes and liver function tests in adults
- BC Guidelines - Viral Hepatitis Testing (2021) · PDF — BC GPAC; testing for hepatitis A, B and C
- BC Guidelines - High Ferritin and Iron Overload: Investigation and Management (2021) · PDF — BC GPAC; high ferritin, hemochromatosis
- Five things to know about ... Drug-induced liver injury (CMAJ) (2021) · PDF — CMAJ 193(9):E310
- Five things to know about ... Alcohol-associated hepatitis (CMAJ) (2023) · PDF — CMAJ 195(16):E588
- AAFP - Mildly Elevated Liver Transaminase Levels: Causes and Evaluation (2017) · 2024 update (AAFP members) — International source: US guidance, not Canadian.
Algorithms and Pathways¶
- Alberta's Pathway Hub - Non-Alcoholic Fatty Liver Disease (NAFLD) (2021) · PDF — Primary Care Alberta pathway; uses the older NAFLD name
- Alberta's Pathway Hub - Cirrhosis Care (2021) · Interactive practitioner pathway — Primary Care Alberta pathway
- Alberta's Pathway Hub - Liver Mass (2025) — Primary Care Alberta pathway for a liver lesion found on imaging
Assessment Tools and Calculators¶
- MDCalc: Fibrosis-4 (FIB-4) Index for Liver Fibrosis — fibrosis risk from age, AST, ALT and platelets
- MDCalc: NAFLD Fibrosis Score — fibrosis risk in fatty liver disease
- MDCalc: MELD Score (12 and older) — severity score for end-stage liver disease
- MDCalc: Child-Pugh Score for Cirrhosis Mortality — cirrhosis severity
- Stanford Medicine 25 - Liver Exam — examining the liver: percussion, palpation and signs of liver disease
Prescribing¶
- RxFiles - Drug Comparison Charts: Hepatitis B and C · PDF — antiviral comparison chart; needs an RxFiles subscription
- RxFiles - Drug Comparison Charts: Weight Loss Approach — weight-management medicines chart; needs an RxFiles subscription
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — NIH database of medicines, herbals and supplements that can injure the liver. International source: US, not Canadian.
No PharmaCare Special Authority criteria for MASLD found (checked 2026-11-08).
Advice and Referral¶
- RACE - Rapid Access to Consultative Expertise — telephone and app advice from BC specialists for family physicians, nurse practitioners and midwives
- Pathways BC - Gastroenterology — login; specialists and clinics, with referral details
- Ontario eConsult (OTNhub) — specialist advice for Ontario physicians and nurse practitioners, usually without a patient referral
Patient Resources¶
- HealthLink BC - Non-Alcoholic Fatty Liver Disease (NAFLD)
- HealthLink BC - Liver Function Tests
- HealthLink BC - Cirrhosis
- Canadian Liver Foundation - Fatty liver disease
Also known as: abnormal liver tests, abnormal liver enzymes, elevated liver enzymes, high liver enzymes, raised liver enzymes, abnormal liver function tests, abnormal LFTs, LFTs, liver function tests, liver blood tests, elevated ALT, high ALT, elevated AST, transaminases, transaminitis, elevated ALP, alkaline phosphatase, GGT, bilirubin, jaundice, cholestasis, MASLD, metabolic dysfunction-associated steatotic liver disease, steatotic liver disease, SLD, NAFLD, non-alcoholic fatty liver disease, nonalcoholic fatty liver, fatty liver, fatty liver disease, hepatic steatosis, MASH, NASH, steatohepatitis, MetALD, alcohol-related liver disease, fibrosis, liver fibrosis, FIB-4, NAFLD fibrosis score, transient elastography, FibroScan, cirrhosis, MELD, Child-Pugh, drug-induced liver injury, DILI, hepatotoxicity, LiverTox, hepatitis B, hepatitis C, hemochromatosis, high ferritin, liver mass, liver lesion, CASL